comprehensive -WSS

comprehensive

author：entertainment 2025-10-02 01:08:35 - browse：4513

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： ADCs take center stage as promising cancer treatments

explore

WSS

Ending health disparities requires full federal government, panel says

Results on Novartis prostate cancer therapy could expand its use

UnitedHealth, Optum discontinue NaviHealth name

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

CZI to create biohub to build anti

UnitedHealth, Optum discontinue NaviHealth name

Wikipedia

comprehensive

explore

As demand for Covid shots wanes, Moderna seeks its next success

Interest rates are at a 22

As demand for Covid shots wanes, Moderna seeks its next success

Smaller biotechs seek to piggyback on weight loss drug boom

Wildfire smoke exposes gaps in outdoor worker protections

FDA clears Verve to begin U.S. study of gene

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Will biotech layoffs continue through 2023?

Peter Hotez and the public health issue of online harassment

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Wikipedia

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Readout LOUD podcast: Live from the 2023 STAT Summit

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Timeline: Special counsel's probe into Trump's handling of classified documents

STAT Readout Newsletter: Biotech news today

Why a market frenzy over new weight loss drugs defies logic

explore

explore

focus

leisure time